HemaFus WT1-mRNA Expression Quantitative Detection Kit

Background

The WT1 gene is located on human chromosome 11p13 and is approximately 56 kb in length. Its coding product can inhibit cells from transitioning from G0 or G1/M to the S phase, thus the WT1 gene is considered a tumor suppressor gene. In leukemia cells, the expression of the WT1 gene is 103-105 times higher compared to normal bone marrow cells. Specifically, it is highly expressed in 80%–90 % of AML patients, where it can be detected in 97% of newly diagnosed AML patients, albeit with varying expression levels. In over 90% of AML patients with high gene expression, the expression levels are reduced after complete remission of chemotherapy, meaning the WT1 gene can be employed as a biomarker for clinical monitoring of minimal residual disease. All current reports suggest that it is crucial to detect the expression level of WT1 in AML patients who have achieved complete remission after chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In AML patients with remission, high expression of WT1 indicates the risk of recurrence.

图1

Detection Process

In this method, RNA is isolated and purified from leukocytes in peripheral blood or bone marrow samples, and cDNA is obtained by reverse transcription to determine the expression level of WT1 genes by real-time Q-PCR. The gene fusion is shown in Figure 2

Figure 2

Quantitative Kit Detection Results

Specimen Requirements

Peripheral blood or bone marrow (3–5 mL) is collected in the EDTA tube and stored at 2–8 °C for not more than 5 days. RNA extraction is performed within 5 days.

References

[1] Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL)(2017).

[2] Leukemia,2003,17(12):2318-2357.

[3] Leukemia (1999)13,1901‒1928.

Ordering Information